Evidence map›Paper›PMID 30132033›Full record

ReviewDiabetologia2018

Development of SGLT1 and SGLT2 inhibitors.

Timo Rieg, Volker Vallon

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 11 pooled it
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 11 syntheses or guidelines pooled it, 358 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Review
  19. Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats.Journal of veterinary pharmacology and therapeutics · 2026
    Article
  20. Review

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Timo RiegDepartment of Molecular Pharmacology and Physiology, University of South Florida, 12901 Bruce B. Downs Blvd, Tampa, FL, 33592, USA. trieg@health.usf.edu.ORCID http://orcid.org/0000-0001-6082-662X
Volker VallonDepartment of Medicine, Division of Nephrology and Hypertension, University of California San Diego, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA. vvallon@ucsd.edu.
University of California San Diego · USUniversity of South Florida · US

Funding

UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3M
Glomerular and Tubular Function in the Diabetic KidneyR01DK112042 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI SCOTT Culver THOMSON, Volker Vallon · 2017 to 2026
$4.1M
Role of Renal and Intestinal AC6 and NHE3 for Phosphate HomeostasisR01DK110621 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI RIEG, TIMO · 2016 to 2020
$1.7M
Unraveling Kidney Physiology, Pathophysiology & Therapeutics: A Modeling ApproachR01DK106102 · NIDDK · DUKE UNIVERSITY · PI LAYTON, ANITA · 2016 to 2019
$1.4M
NIDDK NIH HHS P30 DK079337NIDDK NIH HHS R01 DK106102NIDDK NIH HHS R01 DK110621NIDDK NIH HHS R01 DK112042NIDDK NIH HHS R01DK112042
6 · The paper itself

Abstract

Sodium-glucose cotransporters SGLT1 (encoded by SGLT1, also known as SLC5A1) and SGLT2 (encoded by SGLT2, also known as SLC5A2) are important mediators of epithelial glucose transport. While SGLT1 accounts for most of the dietary glucose uptake in the intestine, SGLT2 is responsible for the majority of glucose reuptake in the tubular system of the kidney, with SGLT1 reabsorbing the remainder of the filtered glucose. As a consequence, mutations in the SLC5A1 gene cause glucose/galactose malabsorption, whereas mutations in SLC5A2 are associated with glucosuria. Since the cloning of SGLT1 more than 30 years ago, big strides have been made in our understanding of these transporters and their suitability as drug targets. Phlorizin, a naturally occurring competitive inhibitor of SGLT1 and SGLT2, provided the first insights into potential efficacy, but its use was hampered by intestinal side effects and a short half-life. Nevertheless, it was a starting point for the development of specific inhibitors of SGLT1 and SGLT2, as well as dual SGLT1/2 inhibitors. Since the approval of the first SGLT2 inhibitor in 2013 by the US Food and Drug Administration, SGLT2 inhibitors have become a new mainstay in the treatment of type 2 diabetes mellitus. They also have beneficial effects on the cardiovascular system (including heart failure) and the kidney. This review focuses on the rationale for the development of individual SGLT2 and SGLT1 inhibitors, as well as dual SGLT1/2 inhibition, including, but not limited to, aspects of genetics, genetically modified mouse models, mathematical modelling and general considerations of drug discovery in the field of metabolism.

Indexed as

AnimalsBlood GlucoseDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic KetoacidosisDisease Models, AnimalDrug DesignGlucoseHumansIntestinal MucosaKidneyMiceMutationPhlorhizinSodium-Glucose Transporter 1Sodium-Glucose Transporter 2Blood GlucoseGlucosePhlorhizinSLC5A1 protein, humanSLC5A2 protein, humanSodium-Glucose Transporter 1Sodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsChronic kidney diseaseDrug developmentHeart failureInhibitorIntestinal glucose transportRenal glucose transportReviewSodium–glucose cotransporterType 1 diabetesType 2 diabetes

Identifiers

PMID30132033
PMCPMC6124499
OpenAlexW2883581800

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.